PPD Stock

PPD Gross Profit

Delisted·Dec 9, 2021

The Gross Profit of PPD (PPD) as of Aug 4, 2026 is 1.80 B USD. In the previous year, Gross Profit was 1.62 B USD — a change of 10.88% (higher).

Gross Profit

1.80 BUSD

YoY

10.88%

Last updated:

Gross Profit of PPD is 2026 1.80 B USD. Gross Profit of PPD was 2025 1.62 B USD. It decreases by 10.88% higher compared to the previous year.

The PPD Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

GROSS MARGIN (%)
Date
GROSS MARGIN (%)
Jan 1, 2018
39.32 base
Jan 1, 2019
40.24 base
Jan 1, 2020
38.42 base
Jan 1, 2021 (e)
29.94 base
Jan 1, 2022 (e)
28.06 base
Jan 1, 2023 (e)
25.62 base
Jan 1, 2024 (e)
24.07 base
Jan 1, 2025 (e)
22.39 base
YEARGROSS MARGIN (%)
2025 est 22.39
2024 est 24.07
2023 est 25.62
2022 est 28.06
2021 est 29.94
2020 38.42
2019 40.24
2018 39.32
2017 48.80
2016 48.25
Access this data via the Eulerpool API

PPD Revenue

PPD Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
3.75 B USD
402.24 M USD
104.19 M USD
Jan 1, 2019
4.03 B USD
371.02 M USD
47.82 M USD
Jan 1, 2020
4.68 B USD
509.43 M USD
153.69 M USD
Jan 1, 2021 (e)
6.01 B USD
0.00 USD
567.21 M USD
Jan 1, 2022 (e)
6.41 B USD
0.00 USD
647.74 M USD
Jan 1, 2023 (e)
7.02 B USD
0.00 USD
736.11 M USD
Jan 1, 2024 (e)
7.47 B USD
0.00 USD
830.35 M USD
Jan 1, 2025 (e)
8.03 B USD
0.00 USD
946.02 M USD

PPD Margins

PPD stock margins

The PPD margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PPD. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PPD.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
39.32 %
10.73 %
2.78 %
Jan 1, 2019
40.24 %
9.20 %
1.19 %
Jan 1, 2020
38.42 %
10.88 %
3.28 %
Jan 1, 2021 (e)
38.42 %
0.00 %
9.44 %
Jan 1, 2022 (e)
38.42 %
0.00 %
10.10 %
Jan 1, 2023 (e)
38.42 %
0.00 %
10.49 %
Jan 1, 2024 (e)
38.42 %
0.00 %
11.11 %
Jan 1, 2025 (e)
38.42 %
0.00 %
11.77 %

PPD Stock analysis

What does PPD do? PPD Inc is a global company for medical research and services that was founded in 1985 and is headquartered in Wilmington, North Carolina, USA. The company is known for its ability to conduct clinical trials and develop research programs for the biopharmaceutical and medical industry. PPD is a leading provider of comprehensive, integrated services for phases I-IV of clinical research, from non-interventional studies to contract research for pharmaceutical and biotech clients. PPD's business model is based on three key pillars to provide customers with a broad portfolio of services: the first pillar is comprehensive clinical research required for drug registration with regulatory authorities, the second pillar focuses on providing research-based data and analytical methods to facilitate decision-making and risk assessment in the healthcare sector, and the third pillar encompasses extensive laboratory analyses and diagnostic tests to improve patient health and support research efforts. PPD has multiple divisions focused on specific markets and customers. The Clinical Trials division offers services for drug development up to approval by regulatory authorities, including the setup and monitoring of clinical trials and statistical analysis of test results. The Data Management division provides data capture and management solutions for clinical trials to ensure high data quality and compliance with regulations. The Medical Monitoring division offers medical consultation and monitoring during clinical trials. PPD also has a division for Real World Evidence studies, which collects data from routine clinical practice to assess the safety and efficacy of drugs. PPD has made some important acquisitions in the past to strengthen its presence in the industry. In 2011, PPD was acquired by private equity firms Carlyle Group and Hellman & Friedman, becoming a private company. In 2020, PPD went public. In 2018, PPD acquired Evidera, a company specializing in clinical epidemiology and outcomes research. In 2019, PPD acquired Q-Squared Solutions, expanding its extensive laboratory analysis and diagnostic testing capabilities. PPD's offerings include a wide range of products and services, including unique planning and implementation solutions that enable efficient conduct of clinical trials. These solutions also include electronic data capture and management systems, as well as statistical analysis tools. PPD also offers specialized services, such as training programs for clinical investigators and staff. PPD aims to enable safe, faster, and cost-effective drug development through clinical research. In the future, PPD will continue to expand its business model and services to meet the needs of its customers in the changing industry and support innovative research programs. PPD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PPD stock

Gross Profit of PPD is 1.80 B USD in 2026.

Gross Profit of PPD changed from 1.62 B USD to 1.80 B USD, representing a 10.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit PPD since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's PPD historically and in real time.

Access this data via the Eulerpool API

Income Statement — PPD

All Key Metrics — PPD